Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (171-180 of 324) with videos related to

Pageof 33
Sort By:
Molecular Therapy. Nucleic Acids|December 5, 2013
Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene SilencingKazuo Suzuki, Shinichiro Hattori, Katherine Marks, et al.
Journal of Virology|January 10, 2014
HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapyJohn M Murray, John J Zaunders, Kristin L McBride, et al.
The Journal of Infectious Diseases|January 21, 2006
Increased plasma interleukin-7 level correlates with decreased CD127 and Increased CD132 extracellular expression on T cell subsets in patients with HIV-1 infectionSarah C Sasson, John J Zaunders, Giulia Zanetti, et al.
Neuroradiology|July 10, 2012
Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapyAlan Winston, Chris Duncombe, Patrick C K Li, et al.
The Journal of Infectious Diseases|April 20, 2005
In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNAPatrick W G Mallon, Patrick Unemori, Rebecca Sedwell, et al.
Journal of Immunological Methods|August 25, 2007
Validation of RNA-based molecular clonotype analysis for virus-specific CD8+ T-cells in formaldehyde-fixed specimens isolated from peripheral bloodDavid van Bockel, David A Price, Tedi E Asher, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 12, 2010
Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled studyAlan Winston, Chris Duncombe, Patrick C K Li, et al.
Plos One|November 9, 2013
HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapyAllison Martin, Cecilia L Moore, Patrick W G Mallon, et al.
Plos One|September 7, 2012
Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infectionElizabeth Hamlyn, Fiona M Ewings, Kholoud Porter, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 30, 2014
Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapyHila Haskelberg, Patrick W G Mallon, Jennifer Hoy, et al.
Pageof 33

Showing results (171-180 of 324) with videos related to

Sort By:
Pageof 33
Molecular Therapy. Nucleic Acids|December 5, 2013
Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene SilencingKazuo Suzuki, Shinichiro Hattori, Katherine Marks, et al.
Journal of Virology|January 10, 2014
HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapyJohn M Murray, John J Zaunders, Kristin L McBride, et al.
The Journal of Infectious Diseases|January 21, 2006
Increased plasma interleukin-7 level correlates with decreased CD127 and Increased CD132 extracellular expression on T cell subsets in patients with HIV-1 infectionSarah C Sasson, John J Zaunders, Giulia Zanetti, et al.
Neuroradiology|July 10, 2012
Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapyAlan Winston, Chris Duncombe, Patrick C K Li, et al.
The Journal of Infectious Diseases|April 20, 2005
In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNAPatrick W G Mallon, Patrick Unemori, Rebecca Sedwell, et al.
Journal of Immunological Methods|August 25, 2007
Validation of RNA-based molecular clonotype analysis for virus-specific CD8+ T-cells in formaldehyde-fixed specimens isolated from peripheral bloodDavid van Bockel, David A Price, Tedi E Asher, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 12, 2010
Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled studyAlan Winston, Chris Duncombe, Patrick C K Li, et al.
Plos One|November 9, 2013
HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapyAllison Martin, Cecilia L Moore, Patrick W G Mallon, et al.
Plos One|September 7, 2012
Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infectionElizabeth Hamlyn, Fiona M Ewings, Kholoud Porter, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 30, 2014
Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapyHila Haskelberg, Patrick W G Mallon, Jennifer Hoy, et al.
Pageof 33